About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker MRK · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
NCT07722611 · Polycythemia Vera
Bomedemstat, Ruxolitinib
MRK
Merck Sharp & Dohme LLC
Phase 2/3Recruiting380Jun 25, 2032Registry ↗
Nov 13, 2026A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
NCT07709000 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
MK-1045, Acetaminophen (or similar antipyretic)
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting
was not yet recruiting
60Nov 16, 2033Registry ↗
Nov 13, 2026A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471 · Follicular Lymphoma
MK-1045, Rituximab
MRK
Merck Sharp & Dohme LLC
Phase 2/3Recruiting960Jul 23, 2032Registry ↗
Nov 13, 2026A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772 · Lymphoma, Non-Hodgkin, Lymphoma, Follicular
MK-1045
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting280Jul 1, 2030Registry ↗
Nov 13, 2026A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC…
NCT07489495 · Carcinoma, Renal Cell
Belzutifan, Zanzalintinib
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting758Nov 27, 2030Registry ↗
Nov 13, 2026A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488 · Bladder Cancer, Urinary Bladder Neoplasms
MK-3120
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting45Jul 30, 2027Registry ↗
Nov 13, 2026A Study of V118E in Healthy Participants (V118E-003)
NCT07168915 · Healthy
V118E, PREVNAR 20™
MRK
Merck Sharp & Dohme LLC
Phase 1Active, not recruiting126Jul 6, 2027Registry ↗
Nov 13, 2026A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubici…
NCT06890884 · Lymphoma, Large B-Cell, Diffuse
Zilovertamab vedotin, Rituximab
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting594Dec 13, 2027Registry ↗
Nov 13, 2026A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
NCT06843447 · Ovarian Cancer Recurrent
Raludotatug Deruxtecan, Carboplatin
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting605Mar 27, 2029Registry ↗
Nov 13, 2026A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (…
NCT06818643 · Advanced Solid Tumors, Malignant Neoplasm
MK-3120
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting270Feb 8, 2028Registry ↗
Nov 13, 2026Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC…
NCT06788912 · Lung Neoplasm Malignant
Pembrolizumab (neoadjuvant), Cisplatin
MRK
Merck Sharp & Dohme LLC
Phase 2Active, not recruiting60Feb 6, 2032Registry ↗
Nov 13, 2026Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U0…
NCT06780111 · Esophageal Squamous Cell Carcinoma
Pembrolizumab, I-DXd
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting298Jan 4, 2032Registry ↗
Nov 13, 2026Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Sq…
NCT06780098 · Lung Neoplasm
R-DXD, I-DXD
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting144Mar 2, 2032Registry ↗
Nov 13, 2026A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide…
NCT06717347 · Diffuse Large B-Cell Lymphoma
Zilovertamab vedotin, Rituximab
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting1,046Jul 2, 2029Registry ↗
Nov 13, 2026Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Pa…
NCT06469944 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma
Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT)
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting160Sep 12, 2029Registry ↗
Nov 13, 2026Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesos…
NCT06353386 · Prostatic Neoplasms, Castration-Resistant
Opevesostat, Olaparib
MRK
Merck Sharp & Dohme LLC
Phase 1/2Active, not recruiting
was recruiting
220Jan 15, 2029Registry ↗
Nov 13, 2026Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624 · Prostate Cancer Metastatic
Opevesostat, Abiraterone acetate
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting1,310Nov 30, 2028Registry ↗
Nov 13, 2026Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure D…
NCT05714085 · Heart Failure, Left Ventricular Systolic Dysfunction
Vericiguat tablet, Vericiguat suspension
MRK
Merck Sharp & Dohme LLC
Phase 2/3Recruiting342Aug 20, 2029Registry ↗
Nov 13, 2026Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inh…
NCT05612035 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disea…
Frespaciguat, Placebo
MRK
Merck Sharp & Dohme LLC
Phase 2Active, not recruiting129Apr 9, 2026Registry ↗
Nov 13, 2026Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic…
NCT04924075 · Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine T…
Belzutifan
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting355Nov 18, 2032Registry ↗
Nov 13, 2026Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Partici…
NCT04895722 · Colorectal Cancer
Pembrolizumab, Pembrolizumab/Quavonlimab
MRK
Merck Sharp & Dohme LLC
Phase 2Completed
was active, not recruiting
302May 21, 2025Registry ↗
Nov 13, 2026Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Current…
NCT03486873 · Solid Tumors, Hematologic Malignancies
Pembrolizumab, Standard of Care (SOC)
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting3,500Aug 4, 2043Registry ↗
Nov 13, 2026Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participant…
NCT02625961 · Bladder Cancer
Pembrolizumab, Pembrolizumab/vibostolimab coformulation
MRK
Merck Sharp & Dohme LLC
Phase 2Terminated296Nov 5, 2025Registry ↗
Nov 13, 2026A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lympho…
NCT02332668 · Melanoma, Lymphoma
Pembrolizumab
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting370Feb 2, 2028Registry ↗
Nov 12, 2026A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on…
NCT07850609 · HIV
Alimatravir
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting
was not yet recruiting
80Dec 2, 2027Registry ↗
Nov 12, 2026A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK…
NCT07705607 · Diabetic Retinopathy, Macular Edema
MK-8748, Aflibercept
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting1,104Nov 30, 2028Registry ↗
Nov 12, 2026A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK…
NCT07705555 · Diabetic Retinopathy, Macular Edema
MK-8748, Aflibercept
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting960Oct 31, 2028Registry ↗
Nov 12, 2026A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
NCT07661108 · Healthy
MK-8527, Probenecid
MRK
Merck Sharp & Dohme LLC
Phase 1Completed
was active, not recruiting
44Oct 28, 2026Registry ↗
Nov 12, 2026A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
NCT07614984 · Lipoprotein(a)
MK-7262, Enlicitide
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting750Oct 12, 2027Registry ↗
Nov 12, 2026A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (…
NCT07554339 · Non-small Cell Lung Cancer
Calderasib, Durvalumab
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting310Dec 15, 2032Registry ↗
Nov 12, 2026A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Acti…
NCT07463183 · Colitis Ulcerative, Ulcerative Colitis
MK-8690, Placebo
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting100Oct 28, 2027Registry ↗
Nov 12, 2026MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-…
NCT07431827 · Non-small Cell Lung Cancer
Calderasib, MK-3475A
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting400Oct 26, 2039Registry ↗
Nov 12, 2026A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following A…
NCT07227402 · Renal Cell Carcinoma
Belzutifan, Zanzalintinib
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting904Feb 27, 2032Registry ↗
Nov 12, 2026A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamo…
NCT07221474 · Squamous Non-small Cell Lung Cancer
Intismeran Autogene, Pembrolizumab
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting180Jul 2, 2029Registry ↗
Nov 12, 2026A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell…
NCT07190248 · Non-small Cell Lung Cancer
Calderasib, Pembrolizumab (+) Berahyaluronidase alfa
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting675Dec 7, 2029Registry ↗
Nov 12, 2026A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-0…
NCT07133633 · Radiographic Axial Spondyloarthritis
Tulisokibart, Placebo
MRK
Merck Sharp & Dohme LLC
Phase 2Active, not recruiting
was recruiting
315Mar 29, 2027Registry ↗
Nov 12, 2026A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With…
NCT07058077 · Heterozygous Familial Hypercholesterolemia (HeFH)
Enlicitide Decanoate, Placebo
MRK
Merck Sharp & Dohme LLC
Phase 2/3Recruiting153Dec 4, 2033Registry ↗
Nov 12, 2026A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colo…
NCT06997497 · Colon Adenocarcinoma, Rectal Adenocarcinoma
Calderasib, Oxaliplatin
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting477Mar 28, 2029Registry ↗
Nov 12, 2026Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With…
NCT06797635 · Breast Neoplasms, Breast Cancer
Patritumab deruxtecan, Pembrolizumab
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting372Dec 31, 2029Registry ↗
Nov 12, 2026A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
NCT06688058 · Healthy
V540D, GARDASIL®9
MRK
Merck Sharp & Dohme LLC
Phase 1Active, not recruiting72Jan 29, 2027Registry ↗
Nov 12, 2026A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant…
NCT06345729 · Non-small Cell Lung Cancer
Calderasib, Placebo
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting348Jan 24, 2028Registry ↗
Nov 10, 2026A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With…
NCT07743164 · Ovarian Cancer, Peritoneal Cancer
R-DXd, Bevacizumab
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting646Aug 31, 2031Registry ↗
Nov 10, 2026A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
NCT07700758 · Malignant Neoplasm
Belzutifan
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting15Jan 2, 2034Registry ↗
Nov 10, 2026A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)
NCT07595263 · Healthy
Ulonivirine, Methadone
MRK
Merck Sharp & Dohme LLC
Phase 1Completed
was recruiting
14Sep 29, 2026Registry ↗
Nov 10, 2026A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT07570173 · B-cell Acute Lymphoblastic Leukemia
MK-1045, Blinatumomab
MRK
Merck Sharp & Dohme LLC
Phase 2/3Recruiting340Oct 18, 2033Registry ↗
Nov 10, 2026A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-…
NCT07419295 · Bladder Cancer
Sacituzumab tirumotecan, Vinflunine
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting590Jul 27, 2029Registry ↗
Nov 10, 2026A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
NCT07405151 · Oesophageal Squamous Cell Carcinoma
I-DXd, Rescue Medication
MRK
Merck Sharp & Dohme LLC
Phase 1/2Recruiting60Jun 12, 2027Registry ↗
Nov 10, 2026A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558 · Ovarian Neoplasms, Ovarian Cancer
Sacituzumab tirumotecan, Bevacizumab
MRK
Merck Sharp & Dohme LLC
Phase 3Recruiting900Feb 25, 2033Registry ↗
Nov 10, 2026KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cel…
NCT07252739 · Malignant Neoplasm
MK-1084, Pembrolizumab
MRK
Merck Sharp & Dohme LLC
Phase 2Recruiting140Nov 15, 2029Registry ↗
Nov 10, 2026A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBI…
NCT07013487 · Healthy
V181, Placebo
MRK
Merck Sharp & Dohme LLC
Phase 3Active, not recruiting12,000Sep 6, 2031Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:14 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances